中国当代医药
中國噹代醫藥
중국당대의약
China Modern Medicine
2015年
29期
61-63,66
,共4页
重组人血管内皮抑制素%晚期非小细胞肺癌%临床效果
重組人血管內皮抑製素%晚期非小細胞肺癌%臨床效果
중조인혈관내피억제소%만기비소세포폐암%림상효과
Recombinant human endostatin%Advanced non-small cell lung cancer%Clinical effect
目的：探讨重组人血管内皮抑制素联合DC方案治疗晚期非小细胞肺癌(NSCLC)的效果。方法选取2013年1~7月本院收治的76例晚期NSCLC患者作为研究对象，根据随机数字表法将其分为A组(37例)和B组(39例)。B组给予DC方案治疗，A组在B组的基础上加用重组人血管内皮抑制素治疗，观察两组的有效率、疾病进展时间(TTP)、中位OS、1年生存率及化疗不良反应发生情况。结果 A组的有效率及临床获益率显著高于B组，差异有统计学意义(P<0.05)。 A组的白细胞降低发生率显著低于B组，差异有统计学意义(P<0.05)。A组的TTP显著长于B组，差异有统计学意义(P<0.01)。A组的中位OS长于B组，差异有统计学意义(P<0.05)。A组的1年生存率高于B组，差异有统计学意义(P<0.05)。结论重组人血管内皮抑制素联合DC方案治疗晚期NSCLC疗效确切，能延长患者的存活时间，不良反应少，值得临床推广应用。
目的：探討重組人血管內皮抑製素聯閤DC方案治療晚期非小細胞肺癌(NSCLC)的效果。方法選取2013年1~7月本院收治的76例晚期NSCLC患者作為研究對象，根據隨機數字錶法將其分為A組(37例)和B組(39例)。B組給予DC方案治療，A組在B組的基礎上加用重組人血管內皮抑製素治療，觀察兩組的有效率、疾病進展時間(TTP)、中位OS、1年生存率及化療不良反應髮生情況。結果 A組的有效率及臨床穫益率顯著高于B組，差異有統計學意義(P<0.05)。 A組的白細胞降低髮生率顯著低于B組，差異有統計學意義(P<0.05)。A組的TTP顯著長于B組，差異有統計學意義(P<0.01)。A組的中位OS長于B組，差異有統計學意義(P<0.05)。A組的1年生存率高于B組，差異有統計學意義(P<0.05)。結論重組人血管內皮抑製素聯閤DC方案治療晚期NSCLC療效確切，能延長患者的存活時間，不良反應少，值得臨床推廣應用。
목적：탐토중조인혈관내피억제소연합DC방안치료만기비소세포폐암(NSCLC)적효과。방법선취2013년1~7월본원수치적76례만기NSCLC환자작위연구대상，근거수궤수자표법장기분위A조(37례)화B조(39례)。B조급여DC방안치료，A조재B조적기출상가용중조인혈관내피억제소치료，관찰량조적유효솔、질병진전시간(TTP)、중위OS、1년생존솔급화료불량반응발생정황。결과 A조적유효솔급림상획익솔현저고우B조，차이유통계학의의(P<0.05)。 A조적백세포강저발생솔현저저우B조，차이유통계학의의(P<0.05)。A조적TTP현저장우B조，차이유통계학의의(P<0.01)。A조적중위OS장우B조，차이유통계학의의(P<0.05)。A조적1년생존솔고우B조，차이유통계학의의(P<0.05)。결론중조인혈관내피억제소연합DC방안치료만기NSCLC료효학절，능연장환자적존활시간，불량반응소，치득림상추엄응용。
Objective To explore the clinical effect of recombinant human endostatin combined with DC regimen in the treatment of advanced non-small cell lung cancer (NSCLC). Methods 76 patients with advanced NSCLC from January 2013 to July in our hospital were selected and divided into group A (37 cases) and group B (39 cases) according to the random number table method.Group B was given DC regimen,group A was given recombinant human endostatin on the basis of the group B.The effective rate,time to progress (TTP),the median overall survival (OS),one-year survival rate and adverse reaction due to chemotherapy was observed in two groups. Results The effective rate and the clinical benefit rate in group A was higher than that in group B,with significant difference (P<0.05).The incidence rate of white blood cell count decrease in group A was lower than that in group B,with significant difference (P<0.05).The TTP in group A was longer than that in group B,with significant difference (P<0.01).The median OS in group A was longer than that in group B,with significant difference (P<0.05).The one-year survival rate in group A was higher than that in group B,with significant difference (P<0.05). Conclusion Recombinant human endostatin combined with docetaxel in the treatment of patients with advanced NSCLC can obtain a definite effect,which can prolong patient’s survival time and less adverse reaction,it is worthy of promotion and application.
